Suppr超能文献

联合使用口服避孕药会使肝素辅因子II水平升高。

Heparin cofactor II levels are increased by the use of combined oral contraceptives.

作者信息

Mackie I J, Segal H, Burren T, Gallimore M, Walshe K J, Robinson G, Machin S J

机构信息

Haematology Department, Middlesex Hospital, London, UK.

出版信息

Blood Coagul Fibrinolysis. 1990 Dec;1(6):647-51.

PMID:2133244
Abstract

Heparin cofactor II (HCII) was assayed by a microtitre amidolytic substrate technique. A linear response was obtained up to 1.5 U/ml and HCII levels were not affected by freezing and thawing the plasma. The assay was validated by comparing HCII and antithrombin III (AT III) levels in AT-III-deficient plasmas and samples from critically ill patients. Higher HCII levels were found in healthy normal women than in healthy normal men (means 1.16 and 0.97 U/ml, respectively, P less than 0.01). A significant increase in HCII levels from 0.86 to 1.10 U/ml (mean values) was seen in healthy normal women starting on combined oral contraceptive (COC) preparations (P less than 0.001). Increased HCII levels were maintained over a 6-month period, but fell towards normal 14 days after stopping COC, although they were still significantly higher than before starting COCs. The discrepancy in HCII level between normal men and women may be due to COC use. In clinical studies, different reference ranges should be used for men and women, and the need for careful questioning about the use of COCs is emphasized.

摘要

采用微量滴定酰胺分解底物技术测定肝素辅因子II(HCII)。在高达1.5 U/ml的浓度范围内获得线性响应,且血浆经冻融后HCII水平不受影响。通过比较抗凝血酶III(AT III)缺乏血浆和危重症患者样本中的HCII和AT III水平对该检测方法进行了验证。健康正常女性的HCII水平高于健康正常男性(均值分别为1.16和0.97 U/ml,P<0.01)。开始服用复方口服避孕药(COC)制剂的健康正常女性中,HCII水平从0.86 U/ml显著升高至1.10 U/ml(均值)(P<0.001)。HCII水平在6个月内持续升高,但在停用COC后14天降至正常水平,尽管仍显著高于开始服用COC之前。正常男性和女性之间HCII水平的差异可能归因于使用COC。在临床研究中,男性和女性应使用不同的参考范围,并强调需要仔细询问COC的使用情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验